PMID- 7718487
OWN - NLM
STAT- MEDLINE
DCOM- 19950519
LR  - 20211231
IS  - 1044-9523 (Print)
IS  - 1044-9523 (Linking)
VI  - 6
IP  - 1
DP  - 1995 Jan
TI  - Arginine-vasopressin induces differentiation of skeletal myogenic cells and 
      up-regulation of myogenin and Myf-5.
PG  - 81-9
AB  - The neurohypophyseal nonapeptide arginine8-vasopressin (AVP) induces 
      phosphoinositide turnover and calcium and pH changes in skeletal myogenic cells 
      in culture. In order to investigate the effect of AVP on skeletal myogenesis, we 
      examined the effect of this hormone on proliferating mononucleated L6 myoblast 
      cultures. Addition of AVP to the medium resulted in the formation of much larger 
      myotubes than those formed in its absence and in a significant increase 
      (2.2-fold) of the percentage of fusion within 3-4 days of treatment. The effect 
      of AVP was dose dependent, in the 10 nM to 1 microM range, and was observed also 
      in primary cultures of mouse satellite cells. The rate of growth of L6 cells was 
      not affected by AVP treatment. The induction of morphological differentiation by 
      AVP correlated with an increased expression of muscle-specific gene products, 
      such as myosin, and an increased number of acetylcholine receptor sites. The 
      accumulation of mRNA transcripts of the acetylcholine receptor subunits was also 
      enhanced by AVP. The mechanism involved in the myogenic action of AVP was 
      investigated. Using AVP-related peptides and antagonists, we found that a 
      specific chemical structure is required and that V1 receptors probably mediate 
      the effect on myogenesis. Expression of muscle-specific transcription factor 
      genes Myf-5 and myogenin and their products are strongly upregulated by AVP. Our 
      findings support the hypothesis that AVP may represent a novel physiological 
      modulator of skeletal muscle differentiation through its action on muscle 
      regulatory genes.
FAU - Nervi, C
AU  - Nervi C
AD  - Institute of Histology and General Embryology, University of Rome La Sapienza, 
      Italy.
FAU - Benedetti, L
AU  - Benedetti L
FAU - Minasi, A
AU  - Minasi A
FAU - Molinaro, M
AU  - Molinaro M
FAU - Adamo, S
AU  - Adamo S
LA  - eng
GR  - 418/TI_/Telethon/Italy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Growth Differ
JT  - Cell growth & differentiation : the molecular biology journal of the American 
      Association for Cancer Research
JID - 9100024
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (Myf5 protein, mouse)
RN  - 0 (Myog protein, mouse)
RN  - 0 (Myog protein, rat)
RN  - 0 (Myogenic Regulatory Factor 5)
RN  - 0 (Myogenin)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Cholinergic)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - EC 3.6.4.1 (Myosins)
SB  - IM
GS  - Myf-5
MH  - Amino Acid Sequence
MH  - Animals
MH  - Arginine Vasopressin/*pharmacology
MH  - Cell Differentiation/drug effects
MH  - Cell Division/drug effects
MH  - Cell Fusion/drug effects
MH  - Cell Line
MH  - *DNA-Binding Proteins
MH  - Gene Expression Regulation/genetics
MH  - Genes, Regulator
MH  - Mice
MH  - Molecular Sequence Data
MH  - Muscle Proteins/biosynthesis/*genetics
MH  - Muscle, Skeletal/*cytology/metabolism
MH  - Myogenic Regulatory Factor 5
MH  - Myogenin/biosynthesis/*genetics
MH  - Myosins/biosynthesis
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Receptors, Cholinergic/metabolism
MH  - Structure-Activity Relationship
MH  - *Trans-Activators
MH  - Transcription Factors/biosynthesis/*genetics
MH  - Up-Regulation/drug effects
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Cell Growth Differ. 1995 Jan;6(1):81-9.